let-7a and its target, insulin-like growth factor 1 receptor, are differentially expressed in recurrent prostate cancer

International Journal of Molecular Medicine

Volumn 36, Issue 5, 2015, Pages 1409-1416

  Tian, Bing ^a   Huo, Nannan ^a   Li, Meng ^a   Li, Yong ^a   He, Zhongzhou ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Inducible nitric oxide synthase; Insulin like growth factor 1 receptor; Let 7a; Proliferation; Prostate cancer

Indexed keywords

MICRORNA; MICRORNA LET 7A; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; IGF1R PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; RECURRENT DISEASE; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PROSTATE TUMOR;

AGED; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOMEDIN;

EID: 84945425520     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2357     Document Type: Article

References (58)

1. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 62: 10 29, 2012.
2. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, and Blute ML. Obesity and survival after radical prostatectomy: A 10 year prospective cohort study. Cancer. 107: 521 529, 2006.
3. Nolan T, and Cogoni C. The long hand of the small RNAs reaches into several levels of gene regulation. Biochem Cell Biol. 82: 472 481, 2004.
4. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, and Tang DG. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor suppressive functions of let 7. Cancer Res. 72: 3393 3404, 2012.
5. Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, and Hornicek F. MicroRNA 199a 3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 10: 1337 1345, 2011.
6. Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, Schwab J, Mankin H, Xavier R, and Hornicek FJ. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA 1 in Met expression. J Orthop Res. 28: 746 752, 2010.
7. Ratert N, Meyer HA, Jung M, Mollenkopf HJ, Wagner I, Miller K, Kilic E, Erbersdobler A, Weikert S, and Jung K. Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One. 7: e39309, 2012.
8. Lang MF, Yang S, Zhao C, Sun G, Murai K, Wu X, Wang J, Gao H, Brown CE, Liu X, et al. Genome wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One. 7: e36248, 2012.
9. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, Nakashima R, Kitade Y, and Naoe T. Role of anti oncomirs miR 143 and 145 in human colorectal tumors. Cancer Gene Ther. 17: 398 408, 2010.
10. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, and Slack FJ. RAS is regulated by the let 7 microRNA family. Cell. 120: 635 647, 2005.
11. Le MT, Teh C, Shyh Chang N, Xie H, Zhou B, Korzh V, Lodish HF, and Lim B. MicroRNA 125b is a novel negative regulator of p53. Genes Dev. 23: 862 876, 2009.
12. Zhang Y, Gao JS, Tang X, Tucker LD, Quesenberry P, Rigoutsos I, and Ramratnam B. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett. 583: 3725 3730, 2009.
13. Garzon R, Marcucci G, and Croce CM. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9: 775 789, 2010.
14. Bader AG, Brown D, and Winkler M. The promise of microRNA replacement therapy. Cancer Res. 70: 7027 7030, 2010.
15. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, Erbersdobler A, Samaan S, Jung K, and Yousef GM. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol. 39: 1183 1192, 2011.
16. Leite KR, Tomiyama A, Reis ST, Sousa Canavez JM, Sañudo A, Dall'Oglio MF, Camara Lopes LH, and Srougi M. MicroRNA 100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 185: 1118 1122, 2011.
17. Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, Xia M, Bouzyk MB, Nam RK, Sugar L, et al. Protein coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol. 179: 46 54, 2011.
18. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, and Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126: 1166 1176, 2010.
19. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, and Kneitz B. Expression of microRNA 221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 127: 394 403, 2010.
20. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, and Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 16: 206 216, 2009.
21. Mackillop WJ, Ciampi A, Till JE, and Buick RN. A stem cell model of human tumor growth: Implications for tumor cell clonogenic assays. J Natl Cancer Inst. 70: 9 16, 1983.
22. Bonnet D, and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hema-Topoietic cell. Nat Med. 3: 730 737, 1997.
23. Al Hajj M, Wicha MS, Benito Hernandez A, Morrison SJ, and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100: 3983 3988, 2003.
24. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, and Dirks PB. Identification of human brain tumour initiating cells. Nature. 432: 396 401, 2004.
25. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, and Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 67: 1030 1037, 2007.
26. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, and Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13: 153 166, 2008.
27. Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65: 10946 10951, 2005.
28. Sugihara E, and Saya H. Complexity of cancer stem cells. Int J Cancer. 132: 1249 1259, 2013.
29. Freitas DP, Teixeira CA, Santos Silva F, Vasconcelos MH, and Almeida GM. Therapy induced enrichment of putative lung cancer stem like cells. Int J Cancer. 134: 1270 1278, 2014.
30. Ratajczak M, Tarnowski M, Staniszewska M, Sroczynski T, and Banach B. Mechanisms of cancer metastasis: Involvement of cancer stem cells? Minerva Med. 101: 179 191, 2010.
31. Chen X, Rycaj K, Liu X, and Tang DG. New insights into prostate cancer stem cells. Cell Cycle. 12: 579 586, 2013.
32. Rane JK, Scaravilli M, Ylipää A, Pellacani D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T, and Maitland NJ. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur Urol. 67: 7 10, 2015.
33. Livak KJ, and Schmittgen TD. Analysis of relative gene expression data using real time quantitative PCR and the 2( Delta Delta C(T)) Method. Methods. 25: 402 408, 2001.
34. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, and Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 169: 517 523, 2003.
35. Brookman Amissah N, Nariculam J, Freeman A, Willamson M, Kirby RS, Masters JR, and Feneley MR. Allelic imbalance at 13q14.2 approximately q14.3 in localized prostate cancer is associated with early biochemical relapse. Cancer Genet Cytogenet. 179: 118 126, 2007.
36. Barron N, Keenan J, Gammell P, Martinez VG, Freeman A, Masters JR, and Clynes M. Biochemical relapse following radical prostatectomy and miR 200a levels in prostate cancer. Prostate. 72: 1193 1199, 2012.
37. Li X, Liu Y, Chen W, Fang Y, Xu H, Zhu HH, Chu M, Li W, Zhuang G, and Gao WQ. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. 5: 9498 9513, 2014.
38. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, and Jacks T. Suppression of non small cell lung tumor development by the let 7 microRNA family. Proc Natl Acad Sci USA. 105: 3903 3908, 2008.
39. Mayr C, Hemann MT, and Bartel DP. Disrupting the pairing between let 7 and Hmga2 enhances oncogenic transformation. Science. 315: 1576 1579, 2007.
40. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, and Gorospe M. HuR recruits let 7/RISC to repress c Myc expression. Genes Dev. 23: 1743 1748, 2009.
41. Barh D, Malhotra R, Ravi B, and Sindhurani P. MicroRNA let. 7: An emerging next generation cancer therapeutic. Curr Oncol. 17: 70 80, 2010.
42. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 16: 430 441, 2010.
43. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, et al. Low level expression of microRNAs let 7d and miR 205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol. 174: 736 745, 2009.
44. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, et al; Australian Ovarian Cancer Study Group: Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high grade serous ovarian cancers. PLoS One 6 e18064 2011.
45. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, et al. let 7 regulates self renewal and tumori-genicity of breast cancer cells. Cell. 131: 1109 1123, 2007.
46. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, and Sarkar FH. Epithelial to mesenchymal transition is mechanis-Tically linked with stem cell signatures in prostate cancer cells. PLoS One. 5: e12445, 2010.
47. Viswanathan SR, Daley GQ, and Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 320: 97 100, 2008.
48. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, Lassus H, Wang L, Katsaros D, Montone K, et al. Double negative feedback loop between reprogramming factor LIN28 and microRNA let 7 regulates aldehyde dehydrogenase 1 positive cancer stem cells. Cancer Res. 70: 9463 9472, 2010.
49. Zhong X, Li N, Liang S, Huang Q, Coukos G, and Zhang L. Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem. 285: 41961 41971, 2010.
50. Ji J, and Wang XW. A Yin Yang balancing act of the lin28/let 7 link in tumorigenesis. J Hepatol. 53: 974 975, 2010.
51. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, and Rustgi AK. LIN28B promotes colon cancer progression and metastasis. Cancer Res. 71: 4260 4268, 2011.
52. Peter ME. Let 7 and miR 200 microRNAs: Guardians against pluripotency and cancer progression. Cell Cycle. 8: 843 852, 2009.
53. Esquela Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, and Slack FJ. The let 7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 7: 759 764, 2008.
54. Kleinberg DL, Feldman M, and Ruan W. IGF I: An essential factor in terminal end bud formation and ductal morphogenesis. J Mammary Gland Biol Neoplasia. 5: 7 17, 2000.
55. Pacher M, Seewald MJ, Mikula M, Oehler S, Mogg M, Vinatzer U, Eger A, Schweifer N, Varecka R, Sommergruber W, et al. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis. 28: 49 59, 2007.
56. Kang BP, Urbonas A, Baddoo A, Baskin S, Malhotra A, and Meggs LG. IGF 1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose. Am J Physiol Renal Physiol. 285: F1013 F1024, 2003.
57. Wei L, Xiao AY, Jin C, Yang A, Lu ZY, and Yu SP. Effects of chloride and potassium channel blockers on apoptotic cell shrinkage and apoptosis in cortical neurons. Pflugers Arch. 448: 325 334, 2004.
58. Jin C, Guo J, Qiu X, Ma K, Xiang M, Zhu X, and Guo J. IGF 1 induces iNOS expression via the p38 MAPK signal pathway in the anti apoptotic process in pulmonary artery smooth muscle cells during PAH. J Recept Signal Transduct Res. 34: 325 331, 2014.